DPT Vaccine0.5 ml

DPT Vaccine is a combination vaccine indicated for active immunization against diphtheria, pertussis (whooping cough), and tetanus. It is a core component of the national Expanded Programme on Immunization (EPI) schedule for infants and young children.

Established / Guideline-Supported Uses

• Primary immunization series: Recommended for all infants as part of routine EPI schedule to induce protective immunity against diphtheria, pertussis, and tetanus before natural exposure risk increases.
• Booster immunization: Recommended booster doses in toddlers and pre-school children to maintain protective antibody levels, per national/WHO immunization schedules.

Not Indicated

DPT Vaccine (pediatric formulation) is not indicated for adolescents or adults; reduced-antigen formulations (e.g., Td/Tdap) are used for older age groups and for wound-management or catch-up boosters, per local guidelines.

Each 0.5 mL dose of Diphtheria + Pertussis + Tetanus [DPT] typically contains purified diphtheria toxoid, purified tetanus toxoid, and inactivated (whole-cell or acellular, depending on manufacturer) Bordetella pertussis antigen(s), adsorbed onto an aluminum-salt adjuvant, with a suitable preservative. Exact antigen content and preservative vary by manufacturer/brand; refer to the specific product's labeling for precise composition.

DPT Vaccine is a sterile, injectable combination vaccine used for active immunization of infants and children against three vaccine-preventable diseases: diphtheria, pertussis, and tetanus. It combines inactivated bacterial toxoids (diphtheria and tetanus) with a pertussis antigen component, adsorbed onto an adjuvant to enhance the immune response. It is administered as part of a multi-dose primary series followed by booster doses under national immunization programs.

DPT Vaccine belongs to the therapeutic class of combined bacterial vaccines (toxoid and inactivated antigen vaccines), used for active immunoprophylaxis rather than treatment of active disease.

Diphtheria + Pertussis + Tetanus [DPT] works by stimulating the recipient's immune system to produce protective antibodies without causing the diseases themselves.

• Diphtheria toxoid and tetanus toxoid are chemically inactivated bacterial exotoxins that retain immunogenicity but not toxicity; they induce antitoxin antibody production that neutralizes the corresponding toxin if the person is later exposed to Corynebacterium diphtheriae or Clostridium tetani.
• Pertussis antigen(s) stimulate antibody and cell-mediated responses against Bordetella pertussis, reducing the risk and severity of whooping cough.
• The aluminum adjuvant prolongs antigen exposure at the injection site and enhances the magnitude of the immune response, improving seroconversion rates after the primary series and booster doses.

DPT Vaccine is for intramuscular (IM) injection only.

• In infants, administer into the anterolateral thigh muscle; in older children, the deltoid muscle of the upper arm may be used.
• Shake the vial/syringe well before use to ensure a uniform suspension.
• Do not administer intravenously or subcutaneously.
• Use a separate syringe and injection site for each vaccine if co-administered with other EPI vaccines.
• Inspect visually for particulate matter or discoloration before administration; discard if present.

DPT Vaccine can generally be co-administered with other routine childhood vaccines (e.g., oral polio, hepatitis B, Hib, pneumococcal, rotavirus vaccines) at different injection sites, without reducing efficacy of either vaccine.

• Immunosuppressive therapy (e.g., high-dose corticosteroids, chemotherapy, radiation): may blunt the immune response to the vaccine; if possible, defer vaccination until therapy is completed, or recognize that a reduced immune response may occur.
• Immunoglobulins or blood products: concurrent administration is not expected to significantly interfere with the toxoid/antigen components of this vaccine (unlike live vaccines), but administration at separate sites is still advisable.

Common, self-limited reactions after DPT Vaccine include:

• Injection-site pain, redness, and swelling
• Fever (usually low-grade)
• Fussiness, irritability, or unusual crying
• Drowsiness or fatigue
• Loss of appetite; occasional vomiting

Less common reactions include high fever (≥40.5°C), inconsolable/persistent crying lasting 3 hours or more, and febrile seizures. Rare reactions include hypotonic-hyporesponsive episode (HHE) and severe allergic reaction (anaphylaxis); see Contraindications and Precautions and Warnings for management guidance.

DPT Vaccine is a pediatric vaccine intended for infants and young children and is not indicated for use in pregnant or lactating women as a maternal immunization product. It is not administered to pregnant women; maternal immunization against tetanus and pertussis, where indicated, uses different adult-formulated vaccines (e.g., Td or Tdap) under separate national guidance. If a woman of childbearing age or a breastfeeding mother has questions about vaccination, she should consult a physician.

Use DPT Vaccine with caution and clinical judgment in the following situations:

• History of a severe reaction to a previous dose (e.g., fever ≥40.5°C, collapse or shock-like state, persistent crying >3 hours, or seizure within 3 days of a previous dose): weigh the benefits and risks of further doses of a pertussis-containing vaccine; an acellular pertussis-containing product may be considered where available.
• Progressive neurological disorder (including uncontrolled epilepsy or progressive encephalopathy): defer the pertussis component until the condition has stabilized and a treatment regimen has been established.
• Moderate to severe acute illness (with or without fever): defer vaccination until the illness resolves; minor illnesses (e.g., mild upper respiratory infection) are not a reason to delay vaccination.
• Bleeding disorders or thrombocytopenia: administer intramuscular injection with caution, using a fine needle and applying firm pressure to the injection site.

As with any injectable vaccine, appropriate medical treatment for a rare anaphylactic reaction must be immediately available, and the vaccinated child should be observed for a short period after administration.

Overdose with DPT Vaccine is unlikely in normal clinical practice, as it is administered as single, measured doses by trained healthcare personnel. If an excessive dose or dosing-interval error occurs, the child should be monitored closely for increased local injection-site reactions or systemic symptoms (e.g., high fever, excessive irritability). Any child suspected of receiving an inappropriate dose should be evaluated by a physician promptly; if severe symptoms (e.g., difficulty breathing, collapse, persistent high fever) occur, seek immediate emergency medical attention.

Store in a refrigerator at 2°C to 8°C. Do not freeze; discard if the vaccine has been frozen. Protect from light. Keep out of reach of children. Discard any opened multi-dose vial per the open-vial policy or manufacturer instructions.

Preterm infants: should be vaccinated with DPT Vaccine according to their chronological age (not adjusted/corrected age), using the standard dose.

Immunocompromised children (including HIV-infected children): may receive this vaccine per the standard schedule, though the immune response and resulting protection may be reduced compared with immunocompetent children.

Children with a family history of seizures or neurological conditions: can generally still be vaccinated on schedule, but see Precautions and Warnings regarding progressive neurological disorders.

DPT Vaccine is given as a time-limited immunization series rather than an ongoing treatment: a primary series of 3 doses in infancy, followed by booster dose(s) in early childhood per the national immunization schedule. No doses are required beyond the scheduled booster(s) unless specifically recommended by national guidelines or a physician (e.g., after an incomplete/interrupted series).

Diphtheria + Pertussis + Tetanus [DPT] falls under the drug/biologic classes: Vaccines > Toxoid vaccines (diphtheria, tetanus) combined with Bacterial antigen vaccine (pertussis); Combination pediatric immunization products.

Diphtheria + Pertussis + Tetanus [DPT] acts by active immunization: the diphtheria and tetanus toxoid components induce toxin-neutralizing antitoxin antibodies, while the pertussis antigen component induces protective antibody and cellular immune responses against Bordetella pertussis. The aluminum-adjuvant formulation enhances antigen presentation and boosts the magnitude and durability of the immune response, enabling long-term protective immunity after completion of the primary series and booster doses.

DPT Vaccine is specifically formulated and approved for use in infants and young children, typically starting from 6 weeks of age, as part of the primary immunization series, with booster doses continuing through the pre-school years per national schedules. Safety and efficacy of this pediatric formulation have not been established for use beyond the recommended pediatric age range (typically up to 6-7 years); older children, adolescents, and adults requiring booster protection should receive age-appropriate reduced-antigen formulations (e.g., Td/Tdap) instead.